(Q38017203)

27 August 2017

Designing immunoconjugates for cancer therapy (English)

1 reference

27 August 2017

Serengulam V Govindan

series ordinal

1

1 reference

PubMed ID

22679911

27 August 2017

David M Goldenberg

series ordinal

2

1 reference

PubMed ID

22679911

27 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

7

1 reference

27 August 2017

873-890

1 reference

Cancer radioimmunotherapy

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Novel radiolabeled antibody conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Brentuximab Vedotin (SGN-35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody conjugate therapeutics: challenges and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Investigational antibody-drug conjugates for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Investigational antibody drug conjugates for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody drug conjugates - Trojan horses in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Targeted cancer therapy: conferring specificity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

New hydrazone derivatives of adriamycin and their immunoconjugates--a correlation between acid stability and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Metabolism of receptor targeted 111In-DTPA-glycoproteins: identification of 111In-DTPA-epsilon-lysine as the primary metabolic and excretory product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Novel peptide linkers for highly potent antibody-auristatin conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Contribution of linker stability to the activities of anticancer immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Tunable degradation of maleimide-thiol adducts in reducing environments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Cell-targeting fusion constructs containing recombinant gelonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Immunocytokines: a novel class of potent armed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.685153

10.1517/14712598.2012.685153

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22679911